[Results of the treatment of myeloma with a vincristine-melphalan combination].
The authors report the results obtained in a series of 20 multiple myelomas by an association Vincristin-Melphalan with a maximum therapeutic survival of 65 months. The median of survival is established at 27 months. The differences are a function of the initial values of the calcemia, the level of hemoglobin, the percentage of medullary plasmocytosis, but the essential factors appear to be the delay in the treatment, the stage of development established according to Salmon and Durie and particularly the presence or absence of a renal involvement. We have seen important fluctuations of certain immune parameters, particularly level of sheep rosettes and B cells detected by immunofluorescence.
D000368:Aged; D001402:B-Lymphocytes; D002452:Cell Count; D004359:Drug Therapy, Combination; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D010950:Plasma Cells / Q000166:cytology; D012397:Rosette Formation; D014750:Vincristine / Q000627:therapeutic use*
D006454:Hemoglobins; D007136:Immunoglobulins; D014750:Vincristine; D008558:Melphalan
Résultats du traitement du myélome par l'association vincristine-melphalan.